If you've opened a magazine, scrolled through social media, or talked to a friend in the last two years, you've probably heard about GLP-1 medications — Ozempic, Wegovy, Mounjaro. The hype is real. So is the confusion.
As a psychiatric mental health nurse practitioner with a specialty in obesity medicine, I see patients every week who come in with either sky-high expectations or serious misconceptions about these medications. My goal here is to give you the clearest, most honest picture I can.
What is a GLP-1, exactly?
GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally releases after you eat. It signals your pancreas to release insulin, tells your liver to slow glucose production, and most importantly for weight, it travels to your brain and says: you're full, slow down.
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) mimic and amplify this signal. They slow gastric emptying, reduce appetite, and over time, help recalibrate the brain's reward response to food.
In the STEP 1 trial, participants taking semaglutide 2.4mg lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% with placebo — a significant and clinically meaningful difference.
— Wilding et al., New England Journal of Medicine, 2021The mental health connection most people miss
Here's what the headlines rarely cover: GLP-1 receptors aren't only in your gut — they're throughout your brain. Emerging research suggests these medications may reduce addictive behaviors, lower anxiety, and improve mood in some patients. Conversely, a subset of patients — particularly those with a history of depression or disordered eating — may experience worsening mood, nausea-driven restriction, or what I call "GLP-1 induced undereating."
This is why a psychiatric assessment before or during GLP-1 therapy is not optional — it's essential. The medication doesn't work in a vacuum. It works in a person.
A 2023 analysis of the FDA adverse event reporting system found reports of suicidal ideation in patients using GLP-1 medications, prompting an ongoing FDA safety review. While causality has not been established, it reinforces the need for mental health monitoring.
— FDA Drug Safety Communication, 2023Who is a good candidate?
GLP-1 medications are generally indicated for adults with a BMI ≥30, or ≥27 with at least one weight-related condition (type 2 diabetes, hypertension, sleep apnea, etc.). But clinical eligibility is just the starting point. In my practice, I also look at:
- History of eating disorders (binge eating, restriction, purging) — requires careful monitoring
- Current psychiatric medications that affect weight or appetite
- Past trauma around food, body image, or weight stigma
- Support systems and behavioral readiness
- Thyroid history (personal or family history of medullary thyroid carcinoma is a contraindication)
What GLP-1s are not
They are not a cure. They are not a replacement for behavioral and psychological work. And they are not equally effective for everyone. Research shows that approximately 10–15% of patients are "non-responders" — they experience little to no weight loss. We don't yet fully understand why, but emerging evidence points to gut microbiome differences, genetic variants in GLP-1 receptor expression, and baseline insulin sensitivity.
Stopping the medication without a maintenance plan is also a real concern. The STEP 4 trial found that patients who discontinued semaglutide regained two-thirds of their lost weight within a year. This isn't a failure of willpower — it reflects the biological nature of obesity as a chronic condition.
Weight regain after discontinuation of semaglutide was approximately 6.9% of body weight within one year, with return of cardiometabolic risk factors, highlighting the need for ongoing treatment strategies.
— Wilding et al., Diabetes, Obesity and Metabolism, 2022My approach at Clarity
When I work with patients on GLP-1 therapy, I integrate psychiatric evaluation, metabolic monitoring, and behavioral support from the beginning. We talk about what the medication can and can't do. We identify any underlying anxiety, depression, or eating patterns that could interfere — or be made worse. And we build a plan that supports you beyond the prescription.
If you're curious about whether GLP-1 therapy might be right for you, I'd love to talk. A single consultation can help clarify a lot.
Wondering if GLP-1 therapy is right for you?
Book a consultation to discuss your options with Amanveer.